Targeting PIKfyve-driven lipid metabolism in pancreatic cancerCaleb Cheng, Arul M. Chinnaiyan, Xuhong Cao et al.|Nature|2025Cited by 37
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Arul M. Chinnaiyan, Yuanyuan Qiao et al.|Proceedings of the National Academy of Sciences|2023Cited by 31
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Caleb Cheng et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyveChungen Li, Ke Ding, Yuanyuan Qiao et al.|Journal of Medicinal Chemistry|2023Cited by 18
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Arul M. Chinnaiyan, Jesse W. Wotring et al.|Proceedings of the National Academy of Sciences|2023Cited by 8